Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies

Drug Delivery

Volumn 19, Issue 5, 2012, Pages 239-246

  Gullapalli, Rampurna ^a,b   Wong, Angelina ^a,c   Brigham, Elizabeth ^a   Kwong, Grace ^a   Wadsworth, Angie ^a   Willits, Christopher ^a   Quinn, Kevin ^a   Goldbach, Erich ^a   Samant, Bhushan ^a  

^a ELAN PHARMACEUTICALS   (United States)

^b Pharmaceutics International Inc (Pii)   (United States)

^c PHARMACYCLICS INC   (United States)

Author keywords

ALZET osmotic pump; Compatibility; Crystallization; Poorly soluble compounds; Solubilization; Stability

Indexed keywords

ELN 481594; ELND 006; LIVER ENZYME; NEW DRUG; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CRYSTALLIZATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; TIMED DRUG RELEASE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG DELIVERY SYSTEMS; FEMALE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; OSMOSIS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS; WATER;

EID: 84864225466     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.691121     Document Type: Article

References (31)

1. ALZET. Technical Information Manual, Durect Corporation, .2008. http://www.alzet.com/resources/documents/TIM2008.pdf. Accessed on December 2011.
2. Arnot MI, Bateson AN, Martin IL. Dimethyl sulfoxide/propylene glycol is a suitable solvent for the delivery of diazepam from osmotic minipumps. J Pharmacol Toxicol Methods 1996;36: 29-31. (Pubitemid 26288693)
3. Herrlich S, Spieth S, Messner S, Zengerle R. Osmotic micropumps for drug delivery. Adv Drug Deliv Rev 2012; doi:10.1016/j. addr.2012.02.003.
4. Theeuwes F, Yum SI. Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann Biomed Eng 1976;4:343-353.
5. Wright JC. Critical variables associated with nonbiodegradable osmotically controlled implants. AAPS J 2010;12:437-442.
6. Barter RA, Klaassen CD. UDP-glucuronosyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. Toxicol Appl Pharmacol 1992;113:36-42.
7. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Kinetics of cellular proliferation after arterial injury. V. Role of acute distension in the induction of smooth muscle proliferation. Lab Invest 1989;60:360-364. (Pubitemid 19095952)
8. Dani BA, DeLuca PP. Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin. AAPS Pharm Sci 2001;3(E27):1-7.
9. Nachemson AK, Lundborg G, Hansson HA. Insulin-like growth factor I promotes nerve regeneration: an experimental study on rat sciatic nerve. Growth Factors 1990;3:309-314.
10. Pellicane JV, DeMaria EJ, Abd-Elfattah A, Reines HD, Vannice JL, Carson KW. Interleukin-1 receptor antagonist improves survival and preserves organ adenosine-5'-triphosphate after hemorrhagic shock. Surgery 1993;114:278-283.
11. Thompson EL, Amber V, Stamp GW, Patterson M, Curtis AE, Cooke JH, Appleby GF, et al. Kisspeptin-54 at high doses acutely induces testicular degeneration in adult male rats via central mechanisms. Br J Pharmacol 2009;156:609-625.
12. Bittner B, Thelly T, Isel H, Mountfield RJ. The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump. Int J Pharm 2000;205: 195-198.
13. Wright JC, Johnson RM, Yum SI. DUROS® osmotic pharmaceutical systems for parenteral & site-directed therapy. Drug Deliv Technol 2003;3:64-73.
14. Bishop SM, Baloian L, Beresini M, Reynolds M, Burdick D, Mordenti J, Thomsen K, Shahrokh Z. Enhancing small molecule solubility with cosolvents: considerations for efficacy studies using mini-infusion pumps. AAPS Annual Meeting and Exposition, New Orleans, LA. 1999. http://www.aapsj.org/abstracts/ AM-1999/2036.htm. Accessed on December 2011.
15. Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol 2006;2:715-731. (Pubitemid 46118317)
16. Bittner B, Isel H, Mountfield RJ. The use of election paramagnetic resonance spectroscopy in early preformulation experiments: the impact of different experimental formulations on the release of a lipophilic spin probe into gastric juice. Eur J Pharm Biopharm 2001;51:159-162. (Pubitemid 32162495)
17. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 2004;30:221-229. (Pubitemid 38420267)
18. Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm 2007;341:1-19. (Pubitemid 47088122)
19. Quinn K, Gullapalli RP, Merisko-Liversidge E, Goldbach E, Wong A, Liversidge GG, Hoffman W, et al. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs. J Pharm Sci 2012;101:1462-1474.
20. Liang E, Liu WJ, Lohr L, Nguyen V, Lin H, Munson ML, Crans G, Cedarbaum J. A Phase 1, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral daily doses of ELND006 in healthy elderly subjects. Alzheimer's and Dementia 2011;7:S465.
21. Elder DP. Effective formulation development strategies for poorly soluble active pharmaceutical ingredients (APIs). Pharm Outsourcing March/April 2011;56-61.
22. Groves MJ, Bassett B, Sheth V. The solubility of 17 beta-oestradiol in aqueous polyethylene glycol 400. J Pharm Pharmacol 1984;36: 799-802. (Pubitemid 15221993)
23. Serajuddin AT, Sheen PC, Augustine MA. Water migration from soft gelatin capsule shell to fill material and its effect on drug solubility. J Pharm Sci 1986;75:62-64. (Pubitemid 16160545)
24. Price JC. Polyethylene glycol. In: Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of pharmaceutical excipients. 5th edition. London: Pharmaceutical Press And washington, DC: American Pharmacists Association, 2006: 545-550.
25. Alzaid® Chemical Compatibility Kit for Alzet® Osmotic Pumps. Durect corporation. http://www.alzet.com/products/documents/alzaidspecs.pdf. Accessed on December 2011.
26. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-230. (Pubitemid 38221966)
27. Weller PJ. Glycofurol. In: Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of pharmaceutical excipients. 5th edition. London: Pharmaceutical Press and Washington, DC: American Pharmacists Association, 2006: 313-314.
28. Owen SC. Alcohol. In: Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of pharmaceutical excipients. 5th edition. London: Pharmaceutical Press and Washington, DC: American Pharmacists Association, 2006:18-20.
29. Owen SC, Weller PJ. Propylene glycol. In: Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of pharmaceutical excipients. 5th edition. London: Pharmaceutical Press and Washington, DC: American Pharmacists Association,2006: 624-626.
30. Singh KK. Polyoxyethylene castor oil derivatives. In: Rowe RC, Sheskey PJ, Owen SC, editors. Handbook of pharmaceutical excipients. 5th edition. London: Pharmaceutical Press and Washington, DC: American Pharmacists Association, 2006:572-579.
31. Cremophor® EL, Technical Leaflet: ME 074 e. BASF Aktiengesellschaft, Ludwigshafen, Germany, 1997.